Pulse Biosciences Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pulse Biosciences, Inc. (PLSE) Misses Q1 EPS by 10c
May 11, 2020 4:52 PM EDTPulse Biosciences, Inc. (NASDAQ: PLSE) reported Q1 EPS of ($0.57), $0.10 worse than the analyst estimate of ($0.47).
Recent Highlights
Completed Pre-Submission meeting with the U.S. Food and Drug Administration (FDA) to establish the criteria for the studies required for a 510(k) submission for the CellFX System for a general indication in aesthetic dermatologyObtained ISO-13485:2016 Quality System Management Certification to begin preparations for... More